RxDoctor Payments Data

Katie Frees

Family · Huntsville, ALNPI 1518427384

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Novo Nordisk at 42.8% of the total. Reporting peaked in 2021 at $1,104 and has fallen 97.9% since, to $23 in 2024.

$1,503in general payments, 2019–2025

Across 177 payments — averaging $8.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$643
  • AbbVie$230
  • Amarin Pharma, Inc.$146
  • Biohaven Pharmaceuticals, Inc.$132
  • Takeda Pharmaceuticals U.S.A., Inc.$121
  • Boehringer Ingelheim$63
  • plus $169 from 6 others

What the payments were for

  • Food & beverage$1,503100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,503 in reported general payments places this provider in the 70th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama →

Other family in Huntsville

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →